Ahmad Abdelraheem Ahmad Abdelraheem <br/><br/>
Low bose cytarabine with or without anthracycline in the induction treatment of elderly patients with acute myeloid leukemia /  
 الجرعات المنخفضة من عقار السيتارابين مع أو بدون عقار الانثراسيكلين كعلاج مبدني لكبار السن من مرضى سرطان الدم الميلودى الحاد 
Ahmad Abdel Raheem Ahmad Abdel Raheem ; Supervised Fouad M. Abu-Taleb , Osman M. Mansour , Nahla El Sharkawy 
 - Cairo :   Ahmad Abdelraheem Ahmad Abdelraheem ,   2011 
 - 187 P. :   charts ;   25cm 
<br/><br/>Thesis (Ph.D.) - Cairo University - National Cancer Institute - Department of Oncology-Medical 
<br/><br/> Acute myelogenous leukemia is a disease of the elderly with median age at diagnosis 60 years, despite an improved molecular understanding of AML, treatment has been largely unsuccessful in the population age 60 and older with most patients dying within one year of diagnosis. To compare the outcome of elderly AML patients receiving low dose cytarabine (LDAC) plus doxorubicin versus low dose cytarabine to identify which one is more suitable for elderly AML patient regarding response rate 
<br/><br/>
<br/><br/><label>Subjects--Index Terms: </label>Acute myelogenous leukemia Elderly Low- dose